The kaposi sarcoma treatment market size was valued at USD 140.2 million in 2023 growing at a CAGR of 4.8% between 2024 and 2032 driven by increasing prevalence of Kaposi sarcoma.
Alternative splicing in classic kaposi sarcoma lesions and in adjacent non-tumor tissues using the RNA-seq data. A total of 1576 differentially expressed regulated alternative splicing events(RASEs) w
Kaposi's sarcoma (KS), is an AIDS-associated neoplasm caused by the KS herpesvirus (KSHV/ HHV-8). KSHV-sarcomagenesis is the consequence of oncogenic viral gene expression as well as host genetic and
Delivery of the sulfated polysaccharide dextrin 2-sulfate by the intraperitoneal route to the lymphatic circulation resulted in a clinically significant improvement in Kaposi’s sarcoma in three patien